Mahindra Manulife Large & Mid Cap Fund
The Scheme seeks long term capital growth through investments in equity and equity related securities of both large cap and mid cap stocks.
Growthvine rating: 2/5 — ranked #23 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹26.54 (as of 2026-10-01) |
|---|
| AUM | ₹2,827 Cr |
|---|
| Expense ratio | 1.68% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Kirti Dalvi |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 9.72% |
|---|
| Sharpe ratio | 0.49 |
|---|
| Standard deviation | 15.27% |
|---|
| Max drawdown | −32.95% |
|---|
| Alpha | 0.25 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 95.9% of NIFTY LargeMidcap 250's upside and 102.4% of its downside.
Market cap allocation
| Large cap | 46.6% |
|---|
| Mid cap | 40.6% |
|---|
| Small cap | 12.8% |
|---|
Concentration
| Top 5 holdings | 15.6% |
|---|
| Top 10 holdings | 26.7% |
|---|
| Total holdings | 70 |
|---|
| Index overlap | 39.7% |
|---|
| Active share | 60.3% |
|---|
Top holdings
- ICICI Bank Ltd. — 4.5%
- Federal Bank Ltd. — 2.9%
- AXIS Bank Ltd. — 2.8%
- Triparty Repo — 2.7%
- IndusInd Bank Ltd. — 2.7%
- Eternal Limited — 2.6%
- HDFC Bank Ltd. — 2.5%
- Glenmark Pharmaceuticals ltd — 2.4%
- Laurus Labs Limited — 2.1%
- SENORES PHARMACEUTICALS LIMITED — 2.1%
Top sectors
- Banking & Financial — 22.8%
- Pharma & Biotech — 12.5%
- Automobile — 7.2%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −2.7% | Q2 | #12 of 38 |
| 2025 | 2.3% | Q3 | #24 of 34 |
| 2024 | 16.6% | Q3 | #22 of 29 |
| 2023 | 32.2% | Q2 | #8 of 28 |
| 2022 | 1.9% | Q2 | #13 of 28 |